Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 2
2010 4
2011 4
2012 3
2013 2
2014 1
2015 4
2016 2
2017 3
2018 1
2021 3
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA; KEYNOTE-716 Investigators. Long GV, et al. Among authors: fukunaga kalabis m. Lancet Oncol. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18. Lancet Oncol. 2022. PMID: 36265502 Clinical Trial.
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.
Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, Gregorio E, Chen Y, Thakur R, Abdel-Mohsen M, Beqiri M, Kiernan M, Perego M, Wang F, Xiao M, Brafford P, Yang X, Xu X, Secreto A, Danet-Desnoyers G, Traum D, Kaestner KH, Huang AC, Hristova D, Wang J, Fukunaga-Kalabis M, Krepler C, Ping-Chen F, Zhou X, Gutierrez A, Rebecca VW, Vonteddu P, Dotiwala F, Bala S, Majumdar S, Dweep H, Wickramasinghe J, Kossenkov AV, Reyes-Arbujas J, Santiago K, Nguyen T, Griss J, Keeney F, Hayden J, Gavin BJ, Weiner D, Montaner LJ, Liu Q, Peiffer L, Becker J, Burton EM, Davies MA, Tetzlaff MT, Muthumani K, Wargo JA, Gabrilovich D, Herlyn M. Somasundaram R, et al. Among authors: fukunaga kalabis m. Nat Commun. 2021 Jan 12;12(1):346. doi: 10.1038/s41467-020-20600-7. Nat Commun. 2021. PMID: 33436641 Free PMC article.
Recent Advances in Melanoma and Melanocyte Biology.
Tsao H, Fukunaga-Kalabis M, Herlyn M. Tsao H, et al. Among authors: fukunaga kalabis m. J Invest Dermatol. 2017 Mar;137(3):557-560. doi: 10.1016/j.jid.2016.11.004. Epub 2017 Jan 12. J Invest Dermatol. 2017. PMID: 28089201 Free article. Review. No abstract available.
What is a good model for melanoma?
Herlyn M, Fukunaga-Kalabis M. Herlyn M, et al. Among authors: fukunaga kalabis m. J Invest Dermatol. 2010 Apr;130(4):911-2. doi: 10.1038/jid.2009.441. J Invest Dermatol. 2010. PMID: 20231823 Free article. No abstract available.
Developmental pathways activated in melanocytes and melanoma.
Liu J, Fukunaga-Kalabis M, Li L, Herlyn M. Liu J, et al. Among authors: fukunaga kalabis m. Arch Biochem Biophys. 2014 Dec 1;563:13-21. doi: 10.1016/j.abb.2014.07.023. Epub 2014 Aug 8. Arch Biochem Biophys. 2014. PMID: 25109840 Free PMC article. Review.
NUMB as a Therapeutic Target for Melanoma.
Hristova DM, Fukumoto T, Takemori C, Gao L, Hua X, Wang JX, Li L, Beqiri M, Watters A, Vultur A, Gimie Y, Rebecca V, Samarkina A, Jimbo H, Nishigori C, Zhang J, Cheng C, Wei Z, Somasundaram R, Fukunaga-Kalabis M, Herlyn M. Hristova DM, et al. Among authors: fukunaga kalabis m. J Invest Dermatol. 2022 Jul;142(7):1882-1892.e5. doi: 10.1016/j.jid.2021.11.027. Epub 2021 Dec 7. J Invest Dermatol. 2022. PMID: 34883044 Free PMC article.
Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma.
Wang JX, Fukunaga-Kalabis M, Herlyn M. Wang JX, et al. Among authors: fukunaga kalabis m. J Cell Commun Signal. 2016 Sep;10(3):191-196. doi: 10.1007/s12079-016-0349-3. Epub 2016 Aug 23. J Cell Commun Signal. 2016. PMID: 27553358 Free PMC article. Review.
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Khattak MA, Luke JJ, Long GV, Ascierto PA, Rutkowski P, Schadendorf D, Robert C, Grob JJ, de la Cruz Merino L, Del Vecchio M, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Carlino MS, Mohr P, De Galitiis F, Ross MI, Eroglu Z, Chen K, Jiang R, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Kirkwood JM. Khattak MA, et al. Among authors: fukunaga kalabis m. Eur J Cancer. 2022 Nov;176:207-217. doi: 10.1016/j.ejca.2022.08.004. Epub 2022 Oct 3. Eur J Cancer. 2022. PMID: 36202690 Free article. Clinical Trial.
Cancer: Complexion matters.
Fukunaga-Kalabis M, Herlyn M. Fukunaga-Kalabis M, et al. Nature. 2012 Nov 15;491(7424):342-3. doi: 10.1038/nature11641. Epub 2012 Oct 31. Nature. 2012. PMID: 23123853 No abstract available.
37 results